AstraZeneca Third Quarter 2026 Earnings Preview
AstraZeneca is scheduled to report its third-quarter 2026 financial results, with analysts projecting revenue of $15.99 billion and a net profit of $3.2 billion.
Stocks · News reference
Jim Cramer: Reliance Is ‘Terrific,’ but He Prefers This Steel Stock
Cramer avoids AstraZeneca, Joby and Grab; favors Trinity, Nucor over Reliance, and praises Simon Property and Federal Realty.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AstraZeneca Participates as Platinum Sponsor for LUNGevity Foundation's 'Every Breath Forward' Initiative
AstraZeneca is serving as a Platinum Sponsor for the LUNGevity Foundation's 'Every Breath Forward' initiative, which aims to honor lives and support the lung cancer community.
Citi Maintains Buy Rating on AstraZeneca
Citi analyst Graham Parry has reaffirmed a buy rating for AstraZeneca, reflecting continued confidence in the company's outlook.
AstraZeneca Launches 'Meet Your Mark' Campaign to Promote Cancer Biomarker Testing
AstraZeneca has introduced a new public health campaign featuring actor Mark-Paul Gosselaar to encourage patients to discuss biomarker testing as a standard part of cancer care.
3 Unstoppable S&P 500 Stocks to Buy Before October Ends
The article recommends three S&P 500 Dividend Kings as attractive investment opportunities: Coca-Cola, Johnson & Johnson, and Federal Realty Investment Trust. All three offer above-market yields and have demonstrated resilience during challenging economic conditions, with recent earnings showing strong performance and raised guidance.
Piper Sandler Maintains Overweight on Federal Realty Investment, Lowers Price Target to $131
Piper Sandler analyst Alexander Goldfarb maintains Federal Realty Investment (NYSE:FRT) with a Overweight and lowers the price target from $149 to $131.